Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
N-Acetylcysteine for Prevention of Contrast-Induced Nephropathy
NCT00808795Phase 3Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Apr 2006
- Primary completion
- Oct 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in contrast-induced nephropathy (CIN) comparing N-acetylcysteine with Placebo (2 arms). Primary endpoint: Incidence of Contrast-Induced Nephropathy at 48 hours. Started Apr 2006; status: completed.
02
Drugs
acetylcysteine
03
Conditions
contrast-induced nephropathy (CIN)
Beyond the preview
Go deeper on NCT00808795.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00808795.